Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in the United States. Mostof the estimated 32,000 annual new cases in the U.S. and 60,000 annual new cases in Europe will die withina year of diagnosis. There is an urgent a need to develop new and better strategies for the treatment ofpancreatic cancer. This will require novel approaches to both chemoprevention and chemotherapy, andphytochemicals offer to possibilty of this. For a cancer cell to develop an alteration in the cellular metabolicprofile must occur. Once the normal pancreatic cell has converted to an cancer cell, then a group of cancercells must recruit additional blood supply to grow and metastasize - a process is termed the angiogenicswitch. We and others have found that genistein, a flavonoid, may be a useful approach in impacting themetabolic profile of the pancreatic cancer cell and may inhibit the factors stimulated by the angiogenicswitch. Preliminary evidence in our laboratory suggests that genistein can alter the pancreatic cancer cellmetabolic profile, inhibit cell growth, induce apoptosis, diminish metastatic spread in vivo, and decreaseangiogenesis. We hypothesize that flavonoids prevent the progression to pancreatic cancer, and thatflavonoids may act as a chemotherapeutic in established pancreatic cancer. We will pursue the followingspecific aims:
Specific Aim I). Determine the ability of flavonoids to prevent the progression of pancreaticintraepithelial neoplasia (PanIN) to invasive pancreatic ductal adenocarcinoma using a novel transgenicpancreatic cancer animal model.
Specific Aim II). Assess the effect of flavonoids on immortalized humanpancreatic cancer cell lines in an orthotopic xenograph model.
Specific Aim III). Determine the impact offlavonoids in patients with pancreatic cancer. To complete these aims we will perform experimentsinvestigating genistein, quercetin, and apigenin in a transgenic model (LSL-KRAS G12D;PDX-1-Cre) thatrecaputulates premalignant and malignant pancreatic lesions. Also we will test these flavonoids in anorthotopic murine model and compare these to standard gemcitabine treatment. Finally, we will takeadvantage our large clinical volume of patients with pancreatic cancer and study the impact of soysupplementation in patients with this disease.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Research Program Projects (P01)
Project #
1P01AT003960-01A1
Application #
7394048
Study Section
Special Emphasis Panel (ZAT1-SM (07))
Project Start
2007-12-01
Project End
2012-09-29
Budget Start
2007-12-01
Budget End
2008-09-29
Support Year
1
Fiscal Year
2007
Total Cost
$77,153
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395
Somlyai, Gábor; Collins, T Que; Meuillet, Emmanuelle J et al. (2017) Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma. Oncotarget 8:50187-50192
Birtolo, Chiara; Go, Vay Liang W; Ptasznik, Andrzej et al. (2016) Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas 45:21-31
Pham, Hung; Hui, Hongxiang; Morvaridi, Susan et al. (2016) A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells. Biochem Biophys Res Commun 475:295-300
Boros, László G; D'Agostino, Dominic P; Katz, Howard E et al. (2016) Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle. Med Hypotheses 87:69-74
Varma, Vijayalakshmi; Boros, László G; Nolen, Greg T et al. (2015) Fructose Alters Intermediary Metabolism of Glucose in Human Adipocytes and Diverts Glucose to Serine Oxidation in the One-Carbon Cycle Energy Producing Pathway. Metabolites 5:364-85
Vaitheesvaran, B; Xu, J; Yee, J et al. (2015) The Warburg effect: a balance of flux analysis. Metabolomics 11:787-796
Gregson, A L; Wang, X; Injean, P et al. (2015) Staphylococcus via an interaction with the ELR+ CXC chemokine ENA-78 is associated with BOS. Am J Transplant 15:792-9
Lu, Qing-Yi; Zhang, Lifeng; Yee, Jennifer K et al. (2015) Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells. Metabolomics 11:71-80

Showing the most recent 10 out of 100 publications